ADIL
Adial·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ADIL
Adial Pharmaceuticals, Inc.
A subsidiary of Adial that focused on developing novel molecules targeting the adenosine receptors
4870 Sadler Road, Suite 300, Glen Allen, Virginia 23060
--
Adial Pharmaceuticals, Inc., was incorporated as a Virginia limited liability company in November 2010. The company is a clinical-stage biopharmaceutical company focused on developing therapies to treat or prevent addiction and related diseases. The Company's investigational new drug candidate, AD04, is in development as a therapeutic agent for the treatment of alcohol use disorder (" AUD "). AD04 was recently studied in a Phase 3 clinical trial designated as the ONWARD trial for the potential treatment of AUD in subjects with certain target genotypes identified using a companion diagnostic genetic test.
Company Financials
EPS
ADIL has released its 2025 Q2 earnings. EPS was reported at -0.18, versus the expected -0.22, beating expectations. The chart below visualizes how ADIL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
